Analysts' Top 5 Price Targets of August 5, 2025
Reading Time: 3 minutes
Fulgent Genetics [US3596641098] UBS upgrades the rating from Neutral to Buy and raises price target from $20 to $30 (53% upside potential) UBS views particularly positively the area of precision diagnostics, which accounts for approximately 60% of Fulgent's total revenue. The investment bank sees upward potential here through market share gains and a more favorable reimbursement situation. Additionally, the anatomical pathology segment, which contributes about 35% of revenue, has reportedly recovered and is no longer considered a "growth diluter."...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
